HC Wainwright Issues Pessimistic Outlook for BDTX Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Black Diamond Therapeutics in a research report issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.32) for the quarter, down from their prior estimate of ($0.31). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

Several other research firms have also commented on BDTX. Stifel Nicolaus decreased their price objective on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research report on Wednesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $14.60.

Black Diamond Therapeutics Stock Down 5.3 %

Black Diamond Therapeutics stock opened at $1.78 on Thursday. Black Diamond Therapeutics has a 52 week low of $1.59 and a 52 week high of $7.66. The firm’s 50-day simple moving average is $2.16 and its 200 day simple moving average is $2.89. The firm has a market capitalization of $100.86 million, a PE ratio of -1.34 and a beta of 2.52.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.03.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. D. E. Shaw & Co. Inc. acquired a new position in shares of Black Diamond Therapeutics during the 4th quarter valued at about $37,000. Intech Investment Management LLC increased its stake in shares of Black Diamond Therapeutics by 49.1% during the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock valued at $41,000 after acquiring an additional 6,340 shares during the last quarter. JPMorgan Chase & Co. increased its position in Black Diamond Therapeutics by 429.6% during the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock worth $41,000 after purchasing an additional 15,355 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Black Diamond Therapeutics during the 4th quarter worth approximately $42,000. Finally, Wells Fargo & Company MN increased its position in Black Diamond Therapeutics by 41.8% during the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock worth $43,000 after purchasing an additional 5,932 shares in the last quarter. Institutional investors and hedge funds own 95.47% of the company’s stock.

Insider Buying and Selling at Black Diamond Therapeutics

In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the company’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the completion of the transaction, the insider now owns 2,733,547 shares of the company’s stock, valued at $5,658,442.29. This represents a 67.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 8.87% of the stock is owned by insiders.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.